Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
150
Recruiting, industry sponsors, Immunology and inflammation, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting150
- Completed727
150 trials
Showing 1 to 25, recently updated first.
AbbVieAbbVie (ABBV)
NCT06977724 · 36 participants (planned) · Start Aug 26, 2025 · Primary completion Mar 2029
Drug: ABBV-319 · For: Dry Eye Syndrome; Systemic Lupus Erythematosus
Sites: Margate, Florida; Tampa, Florida; Orland Park, Illinois · 9 sites in all
AbbVieAbbVie (ABBV)
NCT07607964 · 30 participants (planned) · Start May 28, 2026 · Primary completion Jan 2029
Drug: ABBV-519; ABBV-519 · For: Systemic Lupus Erythematosus; Rheumatoid Arthritis
Sites: Anniston, Alabama; Tustin, California; Clearwater, Florida · 17 sites in all
- Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release FormulationPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07908641 · 114 participants (planned) · Start Nov 18, 2026 · Primary completion Jan 10, 2027
Drug: Apremilast XR; Apremilast IR · For: Psoriasis; Arthritis, Psoriatic; Oral Ulcer
Sites: Daytona Beach, Florida; Dallas, Texas
Agomab Spain S.L.U.Industry
NCT07672574 · 8 participants (planned) · Start Sep 9, 2026 · Primary completion Jan 31, 2027
Drug: Ontunisertib; [14C]ontunisertib and 1 more · For: Fibrostenotic Crohn's Disease
Sites: Nottingham, United Kingdom
- Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem CellsRecruiting
Shenzhen Beike Bio-Technology Co., Ltd.Industry
NCT07041801 · 58 participants (planned) · Start Feb 15, 2025 · Primary completion Sep 5, 2027
Drug: hUC-MSCs treatment (low dose); hUC-MSCs treatment (medium dose) and 3 more · For: Systemic Lupus Erythematosus (SLE)
Sites: Shenzhen, China
Diabetes Free, Inc.Industry
NCT07946367 · 72 participants (planned) · Start Dec 1, 2026 · Primary completion Aug 2028
Drug: DFI205 bispecific antibody · For: Rheumatoid Arthritis (RA); Systemic Lupus Erythematosus (SLE); Systemic Sclerosis (SSc) and 1 more
Sites: Erlangen, Germany
AstraZenecaAstraZeneca (AZN)
NCT06897930 · 150 participants (planned) · Start Apr 21, 2025 · Primary completion May 1, 2029
Drug: AZD0120; Cyclophosphamide and 1 more · For: Lupus Erythematosus, Systemic
Sites: San Francisco, California; Stanford, California; Tampa, Florida · 20 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07665723 · 25 participants (planned) · Start Jun 29, 2026 · Primary completion Jul 31, 2027
Drug: Afimkibart; Caffeine and 4 more · For: Active Ulcerative Colitis
Sites: Chula Vista, California; Margate, Florida; Miami, Florida · 19 sites in all
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07758101 · 88 participants (planned) · Start Aug 21, 2026 · Primary completion Mar 31, 2028
Drug: SHR-7590; Placebo · For: Moderate-to-severe Inflammatory Bowel Disease
Sites: Guangzhou, China; Hangzhou, China
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07412704 · 84 participants (planned) · Start Oct 6, 2026 · Primary completion Oct 30, 2029
Drug: BMS-986528 · For: Arthritis, Rheumatoid
Sites: La Jolla, California; Loma Linda, California; Palo Alto, California · 39 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07171983 · 46 participants (planned) · Start Feb 27, 2026 · Primary completion Jun 28, 2027
Drug: BMS-986454 · For: Rheumatoid Arthritis
Sites: Hyderabad, India; Ahmedabad, India; Bangalore, India · 9 sites in all
- Phase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative ColitisRecruiting
Beijing VDJBio Co., LTD.Industry
NCT07932691 · 48 participants (planned) · Start Aug 9, 2024 · Primary completion Nov 30, 2028
Drug: Recombinant Human Interleukin-2 Fusion Protein with Human Serum Albumin (VDJ010); Placebo · For: Ulcerative Colitis (UC)
Sites: Hefei, China; Beijing, China; Xiamen, China · 6 sites in all
Shanghai Cell Therapy Group Co.,LtdIndustry
NCT07174843 · 20 participants (planned) · Start Sep 9, 2025 · Primary completion Aug 2027
Drug: CD19/CD22/BCMA CAR-T cells(BZE2204) · For: Idiopathic Inflammatory Myopathies(IIM); Immune Thrombocytopenia(ITP); Systemic Lupus Erythematosus(SLE)
Sites: Shanghai, China
Novartis PharmaceuticalsNovartis (NVS)
NCT07604324 · 63 participants (planned) · Start Jun 2, 2026 · Primary completion Jan 27, 2028
Drug: DCY636; Placebo · For: Dermatitis, Atopic
Sites: Fukuoka, Japan
AstraZenecaAstraZeneca (AZN)
NCT07295847 · 27 participants (planned) · Start Jan 9, 2026 · Primary completion Feb 22, 2028
Drug: AZD0120; SOC · For: Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Rheumatoid Arthritis
Sites: Tucson, Arizona; Duarte, California; Stanford, California · 27 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06751238 · 20 participants (planned) · Start Sep 24, 2025 · Primary completion Oct 31, 2029
Drug: Secukinumab · For: Juvenile Psoriatic Arthritis
Sites: Loma Linda, California; Gainesville, Florida; Chicago, Illinois · 11 sites in all
- First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07527923 · 160 participants (planned) · Start May 22, 2026 · Primary completion Aug 14, 2028
Drug: REGN20423 · For: Healthy Volunteer; Atopic Dermatitis
Sites: Birmingham, Alabama; North Little Rock, Arkansas; West Hills, California · 9 sites in all
- A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in AdultsPivotal-lookingRecruiting
NCT07290036 · 392 participants (planned) · Start Dec 10, 2025 · Primary completion May 18, 2028
Drug: Bimekizumab regimen 1 iv; Bimekizumab regimen 2 iv and 1 more · For: Psoriatic Arthritis; Axial Spondyloarthritis
Sites: Peoria, Arizona; Apple Valley, California; Covina, California · 65 sites in all
Huabo Biopharm Co., Ltd.Industry
NCT07920861 · 90 participants (planned) · Start Jan 19, 2026 · Primary completion Dec 31, 2026
Drug: HB0017 Injection · For: Psoriasis; Ankylosing Spondylitis
Sites: Hangzhou, China
- FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and PatientsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06564389 · 119 participants (planned) · Start Nov 5, 2024 · Primary completion Jun 2, 2027
Drug: PF-07832837 · For: Healthy Participants; Atopic Dermatitis
Sites: Anaheim, California; San Diego, California; Miami, Florida · 8 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07747480 · 16 participants (planned) · Start Sep 3, 2026 · Primary completion Mar 5, 2028
Drug: Aletekitug · For: Colitis, Ulcerative
Sites: Oxford, United Kingdom
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07629583 · 46 participants (planned) · Start Nov 2, 2026 · Primary completion Mar 29, 2030
Drug: Cevostamab; Tocilizumab · For: Lupus Erythematosus, Systemic
Sites: Parkville, Australia; Porto Alegre, Brazil; Ribeirão Preto, Brazil · 11 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07649265 · 63 participants (planned) · Start Sep 24, 2026 · Primary completion Nov 20, 2028
Drug: HBM7020 · For: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Systemic Sclerosis and 1 more
Sites: Brisbane, Australia
- A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
Chipscreen Biosciences, Ltd.Industry
NCT07129382 · 220 participants (planned) · Start Sep 8, 2025 · Primary completion Sep 18, 2027
Drug: CS32582 capsule(low dose) or matched placebo; CS32582 capsule(high dose) or matched placebo and 3 more · For: Plaque Psoriasis
Sites: Beijing, China; Chengde, China; Shijiazhuang, China · 11 sites in all
Zai Lab (Shanghai) Co., Ltd.Industry
NCT07235384 · 84 participants (planned) · Start Dec 1, 2025 · Primary completion Dec 28, 2027
Drug: ZL-1503; Placebo and 2 more · For: Atopic Dermatitis (AD)
Sites: Woolloongabba, Australia; Carlton, Australia; Beijing, China · 14 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.